

CLAIMS

We claim:

1. A method of treating a cardiac arrhythmia in an individual comprising administering an effective amount of an NGF antagonist.
2. The method of claim 1, wherein said cardiac arrhythmia comprises sustained ventricular tachycardia.
3. The method of claim 1, wherein said cardiac arrhythmia comprises non-sustained ventricular tachycardia.
4. The method of claim 1, wherein said cardiac arrhythmia comprises ventricular fibrillation.
5. The method of claim 1, wherein said cardiac arrhythmia is associated with sudden cardiac death.
6. The method of claim 1, wherein the NGF antagonist is an anti-NGF antibody.
7. The method of claim 6, wherein the anti-NGF antibody binds to human NGF.
8. The method of claim 6, wherein the binding affinity of the anti-NGF antibody is about 0.1 nM or less than about 0.1 nM.